Ospedale Vito Fazzi

Running trials

• Not yet recruiting

  DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”

  2026-525268-16-00· Phase 2/3· Universita' Degli Studi Di Torino· Source

• Not yet recruiting

  Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.

  2025-523903-31-00· Phase 3· Fondazione IRCCS Istituto Nazionale Dei Tumori· Source

• Recruiting

  Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

  NCT07566156· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· BioNTech SE· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Genmab· Source

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Phase 3· Arcus Biosciences, Inc.· Source

• Recruiting

  CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected metastatic colorectal cancer patients

  2024-519322-20-00· Phase 3· Gruppo Oncologico Dell'Italia Meridionale· Source

• Recruiting

  CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZED STUDY

  2024-517789-41-00· Phase 4· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  Peritoneal Ultrafiltration in Cardio Renal Syndrome.

  NCT03994874· Phase 1/2· Iperboreal Pharma Srl· Source

• Active, not recruiting

  Racial Disparities in Acute Stroke

  NCT06955442· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  NCT06742996· Phase 3· BeOne Medicines· Source

• Recruiting

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· Phase 2/3· Bicara Therapeutics· Source

• Recruiting

  A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients

  NCT05291156· Phase 2· Gruppo Oncologico Dell'Italia Meridionale· Source

• Active, not recruiting

  A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

  NCT06687369· Phase 3· mAbxience Research S.L.· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· OSE Immunotherapeutics· Source

• Recruiting

  A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.

  2023-509340-10-00· Phase 3· OSE Immunotherapeutics· Source

• Active, not recruiting

  Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program

  NCT06253637· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Recruiting

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06452277· Phase 3· Bayer· Source

• Recruiting

  Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer (IMPROVE-2 trial)

  2023-509551-14-00· Phase 3· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source

• Recruiting

  A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

  NCT06389292· Phase 3· Ascentage Pharma Group Inc.· Source

• Recruiting

  A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

  NCT06320067· Phase 3· University College, London· Source

• Not yet recruiting

  Liver Resection and Simultaneous Sleeve Gastrectomy for MS-HCC (LIRESS)

  NCT06060847· Ospedale V. Fazzi· Source

• Recruiting

  Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

  NCT05934084· Fondazione Italiana Linfomi - ETS· Source

• Recruiting

  Study of Olverembatinib (HQP1351) in Patients With CML-CP

  NCT06423911· Phase 3· Ascentage Pharma Group Inc.· Source

• Recruiting

  A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RVU120 in Combination with Venetoclax in Participants with Acute Myeloid Leukemia Who Failed Prior Therapy with Venetoclax and a Hypomethylating Agent (RIVER-81)

  2023-505911-19-00· Phase 2· Ryvu Therapeutics S.A.· Source

• Recruiting

  Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

  NCT06191263· Phase 2· Ryvu Therapeutics SA· Source

• Recruiting

  Global Trial in APG2575 for Patients With CLL/SLL

  NCT06104566· Phase 3· Ascentage Pharma Group Inc.· Source

• Recruiting

  Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

  NCT05694312· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Recruiting

  Rescue Stenting and Intravenous Thrombolysis In Patients With Large Vessel Ischemic Stroke

  NCT06727006· ASST Santi Paolo e Carlo· Source

• Active, not recruiting

  Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL

  NCT05478512· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Recruiting

  Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

  NCT05821556· Phase 2· National Cancer Institute, Naples· Source

• Recruiting

  Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

  NCT04662723· Phase 4· Fondazione Schena· Source

• Active, not recruiting

  Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer

  NCT05578664· Phase 2· Consorzio Oncotech· Source

• Active, not recruiting

  A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

  NCT05526755· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

  NCT05300282· Phase 1/2· Fondazione Italiana Linfomi - ETS· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: SUCCESSOR-2

  2022-500861-29-00· Phase 3· Celgene Corp.· Source

• Active, not recruiting

  Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

  NCT05024773· Phase 3· Fidia Farmaceutici s.p.a.· Source

• Active, not recruiting

  Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

  NCT05306301· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Recruiting

  Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  NCT05429632· Phase 3· Priothera SAS· Source

• Recruiting

  Italian Anderson Fabry Disease Cardiovascular Registry

  NCT06806813· IRCCS Azienda Ospedaliero-Universitaria di Bologna· Source

• Recruiting

  MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

  NCT05255471· Phase 3· National Cancer Institute, Naples· Source

• Active, not recruiting

  A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT05160584· Janssen Pharmaceutica N.V., Belgium· Source

• Active, not recruiting

  Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

  NCT04994717· Phase 3· Amgen· Source

• Active, not recruiting

  Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

  NCT04722848· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Active, not recruiting

  RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL.(REPRAB study- MITO 36)

  2024-518847-40-00· Phase 2· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Active, not recruiting

  CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

  NCT05312398· Phase 2· University of Campania Luigi Vanvitelli· Source

• Active, not recruiting

  Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS

  NCT05027984· Centro per la Lotta Contro l'Infarto - Fondazione Onlus· Source

Showing 50 of 69.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia6 recruiting
• Lung cancer4 recruiting
• Ovarian cancer4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Colorectal cancer3 recruiting
• Kidney cancer3 recruiting
• Prostate cancer3 recruiting
• Metastatic breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• Bladder cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Fabry disease1 recruiting
• Follicular lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• IgA nephropathy1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Obesity1 recruiting
• Pancreatic cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

• Completed

  EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs

  NCT06316128· Heart Care Foundation· Source

• Terminated

  Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

  NCT06268574· Phase 2· Ryvu Therapeutics SA· Source

• Completed

  A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)

  2023-505910-10-00· Phase 2· Ryvu Therapeutics S.A.· Source

• Withdrawn

  R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

  NCT05966233· Phase 2· Fondazione Italiana Linfomi - ETS· Source

• Recruiting

  A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

  NCT06285318· Janssen-Cilag Ltd.· Source

• Completed

  VYxeoS Liposomal Italian Observational Study iN the Real Practice

  NCT06143839· Jazz Pharmaceuticals· Source

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Completed

  The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in patients: MRD positive (persistent or relapsed), patients after haematological and extra-haematological relapse and patients who do not have never achieved remission after any previous treatment.

  NCT04475731· Phase 2· Fondazione Gimema Franco Mandelli Onlus· Source

• Completed

  Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer

  NCT04593381· Gemelli Molise Hospital· Source

• Completed

  The Role of 18F-FDG-PET for Staging and Prognostication

  NCT04600804· Fondazione Italiana Linfomi - ETS· Source

• Completed

  Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

  NCT04471428· Phase 3· Hoffmann-La Roche· Source

• Terminated

  Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

  NCT04433182· Phase 2· Fondazione Italiana Linfomi - ETS· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

  NCT04221945· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)

  NCT04034056· Hoffmann-La Roche· Source

• Completed

  Comparison of CRT-D and CRT-DX Systems (CRT-NEXT)

  NCT03587064· Associazione Portatori Dispositivi Impiantabili Cardiaci· Source

• Completed

  Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

  NCT03556839· Phase 3· Grupo Español de Investigación en Cáncer de Ovario· Source

• Completed

  FIL Study on ABVD DD-DI as Upfront Therapy in HL.

  NCT03159897· Phase 3· Fondazione Italiana Linfomi - ETS· Source

• Completed

  Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)

  NCT03230734· Phase 2· Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.· Source

• Completed

  Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing a drug called Nilotinib versus another called Imatinib with switch to Nilotinib in absence of optimal response.

  NCT02602314· Phase 4· Fondazione Gimema Franco Mandelli Onlus· Source

• Terminated

  Clinical Benefits of the Closed Loop Stimulation in Sinus Node Disease

  NCT02579889· Biotronik SE & Co. KG· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Chronic myeloid leukaemia5 works · 2 trials